Overview

Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and plasma concentration change of YM178 after single- and repeated-administration as oral absorption controlled tablet in healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma China, Inc.
Treatments:
Mirabegron